Search
Viloxazine
go.drugbank.com/drugs/DB09185ApprovedInvestigationalWithdrawnViloxazine is a selective norepinephrine reuptake inhibitor.[L41685] For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. … It was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Monoamine Oxidase A InhibitorsDrometrizole trisiloxane
go.drugbank.com/drugs/DB11585ApprovedThe compound is a lipophilic benzotriazole derivative marketed as Meroxyl XL by L'Oreal, although sunscreens with drometrizole trisiloxane are currently only approved for use in the EU, Canada, Australia … Drometrizole trisiloxane is a photostable UVA and UVB light filter [A33069, L2780, L2781, L2782, L2783, F81].
Mixtures: Anthelios XL Melt-IN Cream, Kiehls Since 1851 Dermatologist Solutions Ultra Light Daily UV Defense Tone Up SPF 50 PA Plus Plus Plus Plus AntipollutionCategories: Compounds used in a research, industrial, or household settingRibavirin
go.drugbank.com/drugs/DB00811ApprovedInvestigationalas an adjunct therapy to various first-line and second-line combination therapies recommended for each genotypes. … When used to treat Hepatitis C virus (HCV) infections, it is always used as a part of combination therapies as ribavirin monotherapy is not efficacious in the treatment of chronic hepatitis C infection
Mixtures: Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules)Rotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalRotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. … However, all Neupro patches in the United States and some of Europe were recalled in 2008 due to delivery mechanism issues. Rotigotine has been authorized as a treatment for RLS since August 2008.
Myrrh
go.drugbank.com/drugs/DB11605ApprovedInvestigationalExtractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free fractions, distillates, residues, obtained from Commiphora abyssinica, Burseraceae.
Mixtures: LA FEMME V Feminine CleanserCemiplimab
go.drugbank.com/drugs/DB14707ApprovedInvestigationalCemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. … [A39201,A254177,L4615] It was later approved to be used in basal cell carcinoma and non-small non-small cell lung cancer.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsSilodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigational[A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada. … Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder
Categories: Drugs Used in Benign Prostatic HypertrophyProducts: SILODOSIN AL 4 MG HKP, SILODOSIN AL 8 MG HKPGlyburide
go.drugbank.com/drugs/DB01016ApprovedInvestigational[L8123] It is typically given to patients who cannot be managed with the standard first line therapy, [metformin]. … Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II.
Categories: Drugs Used in DiabetesSynonyms: 5-chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamideLucinactant
go.drugbank.com/drugs/DB04897ApprovedLucinactant is a new synthetic peptide-containing surfactant for intratracheal use. … It also consists of phospholipids (dipalmitoylphosphatidylcholine, DPPC and palmitoyloleoyl phosphatidylglycerol, POPG) and a fatty acid (palmitic acid).
Vosoritide
go.drugbank.com/drugs/DB11928ApprovedInvestigational[A242277] It results from a gain-of-function missense mutation in _FGFR3_ that results in a dramatic suppression of bone growth, both in volume and in length. … of a peptidase-resistant formulation has allowed for its use as a viable treatment option in achondroplasia.